The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
ONLY
ARTICLE
July 21, 2025
Retifanlimab (Zynyz) for Anal Cancer (online only)
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Retifanlimab (Zynyz) for Anal Cancer (online only)
July 21, 2025 (Issue: 1733)
Retifanlimab-dlwr (Zynyz – Incyte), a programmed
death receptor-1 (PD-1)-blocking antibody, has been
approved by the FDA for use in combination with
carboplatin and paclitaxel for first-line treatment of
unresectable locally recurrent or...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.